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Abstract
The myxoma makes 80–90% of benign cardiac neoplasms. The first symptom in 50% of patients is an embolism resul-
ting from relocation of tumor fragments or blood clots into the bloodstream. Elevated values of acute phase proteins in 
these patients are results of non-specific immune response to an antigen causing the disease. Interleukin 6 (IL-6) plays 
a role in this reaction, modifying inflammatory response by: influence on lymphocyte T differentiation, lymphocyte B 
to plasmocyte transformation, and stimulation of the liver to produce acute phase proteins. Elevated IL-6 is found in 
80% of patients with diagnosed myxoma, which causes it to be an important marker in diagnostic and post-operational 
monitoring. The role in non-specific inflammatory response played by IL-6 in myxoma and autoimmune disorders was 
a cause of many diagnostic mistakes. Available literature does not suggest a coincidence of cardiac myxoma and syste-
mic sclerosis. This is why we would like to present a case report, with special regard to correlation between IL-6 values 
and activity/stage of diagnosed disorders.
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Introduction
Primary cardiac tumors can be benign or malignant. The 
incidence is estimated at 0.0017–0.28% of general count 
of all neoplasms [1]. Myxoma is diagnosed in 80–90% of 
all cases of benign cardiac tumors [2]. In approximately 
75% it is localized in the left atrium, in 18% in the right 
atrium, in 4% in right ventricle, in 3% in left ventricle and 
sporadically on leaflets of the valves [3, 4]. The neoplasm 
can occur at any age, but it is diagnosed most frequently 
between 30th and 60th year of age [5, 6]. Additional symp-
toms that accompany myxoma are non-characteristic and 
include loss of body mass, elevated body temperature, skin 
changes, joint and muscle aches and others, caused by 
presence of tumor in the cavities of heart [6, 7]. Additional 
investigations often show elevation of acute-phase proteins, 
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immunoglobulins, anti-nuclear antibodies (ANA) and 
rheumatoid factor (RF). The abovementioned symptoms 
and laboratory results are called the myxoma syndrome 
[6]. Cardiovascular symptoms are caused by inappropria-
te working of the heart due to tumor mass or vascular 
complications caused by displaced tumor fragment. Left 
atrial localization results in obstruction of blood flow into 
ventricles, which causes symptoms typical for aortic steno-
sis or — rarely — for its insufficiency. Acute left ventricular 
insufficiency or sudden loss of consciousness may be the 
first symptoms of the tumor.
Embolisms that happen in about 50% of patients may 
often be one of the first symptoms of myxoma, and are 
caused by displacement of the tumor fragments or embo-
lisms from the surface of the tumor into vascular system. 
Localization of embolisms depends from localization of 
the tumor or intracardiac connections. Myxomas of left 
ventricle or left atrium cause systemic embolisms often 
localized in the central retinal artery or nervous system 
When localized in either right ventricle or right atrium, this 
neoplasm may cause pulmonary embolisms [7].
General symptoms and the presence of acute-phase 
proteins are characteristic of inflammatory diseases, 
including those with autoimmunological background 
such as systemic diseases of connective tissue. They 
all are result of immune response to an antigen that is 
causing the disease in which interleukin 6 (IL-6) plays 
an important role. IL-6 is a cytokine that modifies im-
mune response through: the influence on lymphocyte T 
differentiation, lymphocyte B transformation and liver 
stimulation to produce acute-phase proteins. Hirano et 
al. have discovered that myxoma cells produce IL-6, which 
may be largely responsible for the myxoma syndrome [8]. 
Increased levels of this cytokine can be found in 80% of 
patients with confirmed diagnosis [7]. Interleukin 6 is at 
present a very important marker for diagnosing myxoma 
and monitoring after operation. Additionally, a correlation 
between systemic sclerosis, especially of the type com-
plicated by interstitial lung disease, and concentration of 
IL-6 has been proven [9, 10]. The participation of IL-6 in 
non-specific immune response in myxoma and autoim-
mune diseases has been the cause of diagnostic errors. 
There have been situations where myxomas have been 
primarily diagnosed as rheumatoid disorders [6, 9, 11, 
12]. Based on available literature, we can conclude that 
the coexistence of systemic sclerosis and myxoma has 
not been previously described. This is the reason why 
we present the case of a patient with systemic sclerosis 
and asymptomatic right atrial myxoma, with special at-
tention paid to connection between IL-6 and activity of 
abovementioned disorders.
Case report
A 55-year-old, previously healthy male was admitted to 
the Department of Rheumatology and Internal Diseases 
PUM with suspicion of systemic sclerosis. He complained 
of skin hardening and thickening on the face, neck, chest, 
forearms, hands, thimble-like scars and ulcers of fingertips, 
skin discoloration, Raynaud symptom, decrease tolerance 
to physical exertion, chest pains not related to exercise, 
heartburn, and body mass loss. There was a silent diastolic 
heart murmur in Erb’s point.
Laboratory examinations revealed: ESR increased 
to 28 mm/h, reticulocytosis 56‰, microalbuminuria — 
0.65 mg/l, increased concentration of creatinine phosp-
hokinase — 338 U/L. Conducted serological examinations 
have shown the presence of anti-nuclear antibodies (ANA) 
of 1:2560 titer with speckled staining pattern. Other an-
tibodies like anti-centromere (ACA), anti-topoisomerase-I 
(Scl-70), anti-endothelial cells (AECA), granulocyte cyto-
plasm (ANCA) and anti-cardiolipin antibodies as well as 
krioglobulin and immunological complexes were not found.
Esophageal scintigraphy have revealed peristalsis 
disturbance, and gastroduodenoscopy have shown an esop-
hageal inflammation. High definition computed tomography 
(HDCT) revealed interstitial lung disease.
Based on clinical symptoms and additional exami-
nations, a systemic scleroderma with large areas of the 
skin being affected was diagnosed. Esophagus and lungs 
also were affected. Diagnosis was established according 
to American Rheumatology Association (ARA) criteria. 
Cyclophosphamide in doses of 600 mg/m2 administered 
in 30 day intervals during first 6 months of therapy, and 
every other month in the next 18 months of therapy. At 
present, the patient is receiving cyclophosphamide in this 
dose every third month.
During the first hospitalization after 1st dose of cyclo-
phosphamide was administered, the patient underwent an 
echocardiography as a routine examination, which revealed 
the tumor of the right atrium to be 33 mm × 51 mm in 
size, pedunculated by interatrial septum, movable, and 
of diversified structure (Figure 1). Due to urgent need of 
operation, a coronary angiography was conducted the same 
day. Significant stenoses of proximal segment of the left 
anterior descending artery and proximal segment of the 
second marginal branch were found.
The patient underwent an operation to remove the 
atrial tumor and to implant coronary artery bypass graft. 
Histopathological examination revealed a myxoma.
The concentration of IL-6 was measured in this patient 
prior to the operation, and was monitored afterwards. Pre-
-operational cytokine concentration reached 11.7 pg/ml, 
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of coincidence of systemic scleroderma and myxoma has 
not been described in literature.
In systemic scleroderma, an important role in vascular 
damage, especially the beginnings of fibrosis process, is given 
to cytokines: IL-2, IL-6, and TNF-alfa. Lymphocytes are the 
source of those cytokines, and IL-6 sources are lymphocytes 
Th2, and other non-immunological cells including fibroblasts. 
Needleman et al. have proven that fibroblasts in systemic 
scleroderma produce 30 times more IL-6 than fibroblasts 
from control group [13]. It has also been proven that the 
concentration of IL-6 is connected with the activity of systemic 
scleroderma and acts as a prognostic factor for organ lesions, 
especially those occurring in the lungs [10, 14]. Similar to our 
patient, individuals having large areas of the skin affected are 
more likely to have IL-6 levels increased. Despite a decrease 
in IL-6 values in our patient, systemic scleroderma symptoms 
were still present, but with lesser intensity.
The question is: Whether the systemic scleroderma 
symptoms were caused by two coincidental diseases or 
were connected by a chain of etiopthogenetic events? 
Myxoma produces IL-6, which is crucial in the pathoge-
nesis of scleroderma. It is also important to ask whether 
scleroderma symptoms are a paraneoplastic syndrome in 
case of myxoma.
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being nearly five times greater than reference value, 
which should be below 2.5 pg/ml. After 1 month from 
operation, IL-concentration decreased nearly by a half, 
reaching 6.9 pg/ml, and 4 months later this value was 
3.0 pg/ml. Echocardiography did not show any recurrence 
of the tumor. Presently, the patient is regularly monitored 
by a cardiologist and a rheumatologist; he also underwent 
a proper rehabilitation therapy and returned to good phy-
sical condition.
Discussion
In presented case a myxoma of the right atrium was re-
vealed during routine diagnostics of the cardiovascular 
system of the patient suffering from systemic scleroderma. 
The tumor was asymptomatic. IL-6 concentration before 
operation was considerably elevated, and was systemati-
cally decreasing after tumor removal, having never reached 
the appropriate values.
The systemic symptoms due to immunological respon-
se, which are accompanied by IL-6 elevation in case of 
myxoma, have been misleading in the past. There have 
been cases described, where myxoma was primarily diag-
nosed as systemic lupus erythematosus, polymyositis, 
antiphospholipid syndrome or systemic vasculitis [7, 9, 
11, 12]. After the removal of the tumor all changes con-
nected with immunological response were alleviated, and 
the IL-6 levels normalized. To our best knowledge, a case 
Figure 1. The echocardiographic 2D four-chamber apical projection, which showed the tumor of the right atrium 33 mm × 51 mm in size, 
pedunculated by interatrial septum, movable, and of diversified structure
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Streszczenie
Śluzak stanowi 80–90% łagodnych nowotworów serca. U 50% pacjentów objawia się zatorowością związaną z uwal-
nianiem się jego fragmentów do krwiobiegu. Podwyższone wartości białek ostrej fazy u tych pacjentów są rezultatem 
niespecyficznej odpowiedzi układu odpornościowego na antygen nowotworu. Interleukina 6 (IL-6) odgrywa rolę w tej 
odpowiedzi, modyfikując reakcję zapalną poprzez wpływ na różnicowanie się limfocytów T, transformację limfocytów 
B w plazmocyty i stymulację wątroby do produkcji białek ostrej fazy. Podwyższone stężenia IL-6 obserwuje się u 80% 
pacjentów z rozpoznanym śluzakiem, co czyni ją ważnym markerem w diagnostyce i monitorowaniu pooperacyjnych na-
wrotów guza. Rola, jaką IL-6 odgrywa w śluzaku i chorobach o podłożu autoimmunologicznym, była przyczyną częstych 
pomyłek diagnostycznych. Dlatego autorzy prezentują przypadek ze szczególnym uwzględnieniem korelacji między 
wartościami IL-6 a aktywnością i zaawansowaniem współistniejących chorób.
Słowa kluczowe: śluzak, interleukina 6
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